Advertisement

Topics

KOL Perspectives: Cardiovascular safety profile of JAK inhibitors in Rheumatoid Arthritis [Report Updated: 01022018] Prices from USD $2500

08:57 EDT 16 Oct 2018 | BioPortfolio Report Blog

KOL Perspectives: Cardiovascular safety profile of JAK inhibitors in Rheumatoid Arthritis


Summary


This KOL Insight briefing focuses on KOL opinions of the safety of JAK inhibitors in rheumatoid arthritis RA.


The briefing includes analysis of KOL opinion on the following topic areas

Baricitinib safety profile with regards to cardiovascular signal

Tofacitinib safety profile with regards to cardiovascular signal

Upadacitinib safety profile with regards to cardiovascular signal

Filgotinib safety profile with regards to cardiovascular signal

Most favorable JAK inhibitor with regards to cardiovascular safety

Extent in which thromboembolic events is a class effect across all JAK inhibitors

Additional studies / actions required to mitigate concerns around cardiovascular safety in the JAK inhibitors class


Key Highlights


Majority of KOLs acknowledged that there was a CV signal with baricitinib in RA, although many flagged this was not necessarily a concern

While KOLs generally had a positive opinion of tofacitinib's CV risk profile, many stated the need for more safety data

Most KOLs highlighted the need for additional data before drawing conclusions regarding upadacitinib's CV safety profile.


Scope


The insight briefing is based on Sociable Pharma's analysis of primary research with our RA key opinion leaders KOLs

In total, we conducted interviews with 10 KOLs: Five Europebased five USbased

Interviews conducted in December 2017

KOL data is analyzed to produce: Charts summarizing KOL opinions

Chart callouts of key information details

KOL quotes

Summary of KOL reporting trends

Insight from Sociable Pharma's analysts.


Reasons to buy


Combines Qualitative semiquantitative insight from key opinion leaders on "Cardiovascular safety profile of JAK inhibitors in Rheumatoid Arthritis".

Includes insight recommendations from our diseasespecific healthcare analysts

Utilizes independent expert viewpoints to validate the impact of new clinical data emerging trends on management of rheumatoid arthritis

Provides costeffective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

Original Article: KOL Perspectives: Cardiovascular safety profile of JAK inhibitors in Rheumatoid Arthritis [Report Updated: 01022018] Prices from USD $2500

NEXT ARTICLE

More From BioPortfolio on "KOL Perspectives: Cardiovascular safety profile of JAK inhibitors in Rheumatoid Arthritis [Report Updated: 01022018] Prices from USD $2500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...